Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
07 Octubre 2024 - 8:00AM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing targeted therapies for patients with
RAS-addicted cancers, today announced seven oral and poster
presentations will be featured at the 2024 AACR-NCI-EORTC Symposium
on Molecular Targets and Cancer Therapeutics (“Triple Meeting”).
The conference is being held October 23-25, 2024 in Barcelona,
Spain.
Two late-breaking presentations will feature new
clinical data from patients treated for PDAC, including updated
safety and efficacy data from the ongoing RMC-6236 monotherapy
study and initial safety and antitumor activity data from the
first-in-human monotherapy study of RMC-9805.
Details of the presentations are listed
below:
Revolution Medicines Late Breaking
Presentations:
Title: |
Updated safety and efficacy from a Phase 1 study of RMC-6236, a
RAS(ON) multi-selective, tri-complex inhibitor, in patients with
RAS mutant pancreatic ductal adenocarcinoma (PDAC) |
Presenter: |
Brian Wolpin, M.D., M.P.H., Dana-Farber Cancer Institute |
Abstract Number: |
514LBA |
Session: |
Late Breaking Posters |
Date/Time: |
12:00 p.m. – 7:00 p.m. CEST on October 23, 2024 9:00 a.m. – 5:30
p.m. CEST on October 24, 20249:00 a.m. – 3:00 p.m. CEST on October
25, 2024 |
|
|
Title: |
Preliminary safety, pharmacokinetics, and antitumor activity of
RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in
patients with KRAS G12D pancreatic ductaladenocarcinoma (PDAC) from
a Phase 1 study in advanced solid tumors |
Presenter: |
David S. Hong, M.D., MD Anderson Cancer Center |
Abstract Number: |
502LBA |
Session: |
Late Breaking Abstracts and Proffered Papers: Novel discoveries in
drug development |
Date/Time |
4:12 – 4:24 p.m. CEST on October 25, 2024 |
|
|
Additional Revolution Medicines
Presentations:
Title: |
Selective Inhibition of Active KRAS G13C with RMC-8839 Reveals an
Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild-Type
RAS Isoforms |
Presenter: |
Kyle Seamon, Ph.D. |
Abstract Number: |
92 |
Session: |
Molecular Targeted Agents |
Date/Time: |
12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23 |
|
|
Title: |
The RAS(ON) Multi-Selective Inhibitor RMC-6236 Synergizes with T
Cell-Directed Immunotherapies to Extend Durability of Antitumor
Activity in Preclinical RAS-Driven Cancer Models |
Presenter: |
Elsa Quintana, Pharm.D., Ph.D. |
Abstract Number: |
307 |
Session: |
Translational Studies |
Date/Time |
9:00 a.m. – 5:30 p.m. CEST on Thursday, October 24 |
|
|
Title: |
Combination of RAS(ON) Multi-Selective and G12D-Selective
Inhibitors Improves Antitumor Activity and Enhances Antitumor
Immunity in Preclinical Models of KRAS G12D-Driven Cancers |
Presenter: |
Mallika Singh, Ph.D. |
Abstract Number: |
300 |
Session: |
Translational Studies |
Date/Time: |
9:00 a.m. – 5:30 p.m. CEST on Thursday, October 24 |
|
|
Collaborator Presentations:
Title: |
Preclinical Evaluation of RMC-7977, a Multi-Selective RAS(ON)
Inhibitor, as a Therapeutic Strategy for KRAS-Mutant
Cholangiocarcinoma |
Presenter: |
Rodrigo Entrialgo-Cadierno, M.D., Universidad de Navarra |
Abstract Number: |
297 |
Session: |
Translational Studies |
Date/Time |
9:00 a.m. – 5:30 p.m. CEST on Thursday, October 24, 2024 |
|
|
Title: |
Targeting KRAS codon 13 mutations using direct combination
approaches in non-small cell lung cancer |
Presenter: |
Dr. Helen Adderley, The University of Manchester and The Christie
NHS Foundation Trust |
Abstract Number: |
113 |
Session: |
New Drugs |
Date/Time: |
12:00 p.m. – 7:00 p.m. CEST on October 23, 2024 |
|
|
Investor WebcastRevolution
Medicines will host an investor webcast focused on PDAC data from
the RMC-6236 and RMC-9805 monotherapy studies on Friday, October
25, 2024, following the AACR-NCI-EORTC Symposium’s Late-Breaking
Session. Details for the webcast will be forthcoming and available
on the Investors section of the Revolution Medicines website at
https://ir.revmed.com/events-and-presentations.
Additional updates on the company’s three
RAS(ON) inhibitor clinical development programs will be provided
later in the quarter.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage
oncology company developing novel targeted therapies for
RAS-addicted cancers. The company’s R&D pipeline comprises
RAS(ON) inhibitors designed to suppress diverse oncogenic variants
of RAS proteins, and RAS companion inhibitors for use in
combination treatment strategies. The company’s RAS(ON) inhibitors
RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON)
G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective
inhibitor, are currently in clinical development. Additional
RAS(ON) mutant-selective inhibitors in the company’s development
pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839
(G13C), in addition to RAS companion inhibitors RMC-4630 and
RMC-5552.
Forward Looking Statements This
press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered "forward-looking statements," including
without limitation statements regarding the company’s planned
presentations and events. Forward-looking statements are typically,
but not always, identified by the use of words such as "may,"
"will," "would," "believe," "intend," "plan," "anticipate,"
"estimate," "expect," and other similar terminology indicating
future results. Such forward-looking statements are subject to
substantial risks and uncertainties that could cause the company’s
development programs, future results, performance or achievements
to differ materially from those anticipated in the forward-looking
statements. Such risks and uncertainties include without limitation
risks and uncertainties inherent in the drug development process,
including the company’s programs’ current stage of development, the
process of designing and conducting preclinical and clinical
trials, risks that the results of prior clinical trials may not be
predictive of future clinical trials, clinical efficacy, or other
future results, the regulatory approval processes, the timing of
regulatory filings, the challenges associated with manufacturing
drug products, the company’s ability to successfully establish,
protect and defend its intellectual property, other matters that
could affect the sufficiency of the company’s capital resources to
fund operations, reliance on third parties for manufacturing and
development efforts, changes in the competitive landscape, and the
effects on the company’s business of the global events, such as
international conflicts or global pandemics. For a further
description of the risks and uncertainties that could cause actual
results to differ from those anticipated in these forward-looking
statements, as well as risks relating to the business of Revolution
Medicines in general, see Revolution Medicines’ Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (the
“SEC”) on August 7, 2024, and its future periodic reports to be
filed with the SEC. Except as required by law, Revolution Medicines
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances, or to reflect
the occurrence of unanticipated events.
Revolution Medicines Media & Investor Contacts:
media@revmed.com
investors@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Revolution Medicines (NASDAQ:RVMD)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024